Numerate, a biotechnology company leveraging a novel drug engineering process to design lead-stage drug compounds, announced today that it has completed a $4 million Series A.
From what I can tell, the company is working on the holy grail of in silico drug discovery. Add some inputs, out comes the list of compounds to synthesize. I work for a company that relies heavily on structure activity relationships between virtual molecules and receptor models and all I can say is… good luck.
Numerate Completes $4 Million Financing
-(Via Business Wire Health News.)
Theoretically Related Posts
This post was constructed by .
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Add New Comment
Thanks. Your comment is awaiting approval by a moderator.
Do you already have an account? Log in and claim this comment.
Add New Comment
Trackbacks
(Trackback URL)